en Radiation Biology Radiation Biology تحقيق بديع Original Research <div style="text-align: justify;"><span style="font-size:10pt"><span style="text-justify:newspaper"><span style="text-kashida-space:50%"><span style="line-height:119%"><span style="font-family:Calibri"><span style="color:black"><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-style:italic"><span style="font-weight:bold"><span style="language:en-US">Background</span></span></span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-weight:bold"><span style="language:en-US">:</span></span></span></span></span> <span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:black"><span style="language:en-US">The purpose of this study is to introduce a novel brachytherapy template called the Medanta anterior oblique‑lateral oblique template (MAOLOT), which has been designed for carcinoma cervix, and conduct its dosimetric comparison with Martinez universal perineal interstitial template (MUPIT). </span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-style:italic"><span style="font-weight:bold"><span style="language:en-US">Materials and Methods</span></span></span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-weight:bold"><span style="language:en-US">:</span></span></span></span></span> <span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:black"><span style="language:en-US">Ten patients were chosen for this study with twelve intracavitary (IC) and/or interstitial (IS) applications. Plans were generated with basal points (BP), target points (TP), and inverse plan simulated annealing (IPSA) along with local graphical optimization (LGrO). Dosimetric and volumetric quantifiers including conformal index (COIN), dose non-uniformity ratio (DNR), dose homogeneity index (DHI), target dose homogeneity index (TDHI), and overdose volume index (OVI) were evaluated. </span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-style:italic"><span style="font-weight:bold"><span style="language:en-US">Results</span></span></span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-weight:bold"><span style="language:en-US">:</span></span></span></span></span> <span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:black"><span style="language:en-US">IPSA provided a better solution for DNR (range 0.25-0.48, p=0.04) in MUPIT and BP+LGrO method was appreciable (p=0.08) in OVI. Mean doses of D90, D95, and D98 of targets of LGrO plan were greater than their respective counterparts. Dose to 1cc and 2cc bladder was the highest for IPSA+LGrO plans as compared to forward optimization plans. Better COIN values were obtained for BP and TP plans with LGrO (p=0.043 (BP+LGrO), p=0.022 (TP+LGrO)). Mean EQD2 dose of 1cc and 2cc bladder was the highest for the IPSA plan as compared to other forward optimization plans. </span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-style:italic"><span style="font-weight:bold"><span style="language:en-US">Conclusion</span></span></span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-weight:bold"><span style="language:en-US">:</span></span></span></span></span> <span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:black"><span style="language:en-US">In IC+IS application, small adjustments using LGrO improves the target coverage and reduces the normal structure dose. IPSA provides better results if plan evaluation is performed carefully. MAOLOT creates the intracavitary and interstitial dose distribution, which is comparable to MUPIT.</span></span></span></span></span></span></span></span></span></span></div> Image guided brachytherapy, optimization, intracavitary, interstitial, cervical cancer. 593 600 http://ijrr.com/browse.php?a_code=A-10-1-950&slc_lang=en&sid=1 V. Kaliyaperumal venkphysics@gmail.com 7900319475328460022049 7900319475328460022049 Yes Division Of Radiation Oncology, Medanta Cancer Institute, Medanta The Medicity, Gurgaon, Haryana, India S. Banerjee 7900319475328460022050 7900319475328460022050 No Division Of Radiation Oncology, Medanta Cancer Institute, Medanta The Medicity, Gurgaon, Haryana, India T. Kataria 7900319475328460022051 7900319475328460022051 No Division Of Radiation Oncology, Medanta Cancer Institute, Medanta The Medicity, Gurgaon, Haryana, India S.K. Abraham 7900319475328460022052 7900319475328460022052 No Division Of Radiation Oncology, Medanta Cancer Institute, Medanta The Medicity, Gurgaon, Haryana, India M. Veni S 7900319475328460022053 7900319475328460022053 No Division Of Radiation Oncology, Medanta Cancer Institute, Medanta The Medicity, Gurgaon, Haryana, India S. Tamilselvan 7900319475328460022054 7900319475328460022054 No Division Of Radiation Oncology, Medanta Cancer Institute, Medanta The Medicity, Gurgaon, Haryana, India D. Gupta 7900319475328460022055 7900319475328460022055 No Division Of Radiation Oncology, Medanta Cancer Institute, Medanta The Medicity, Gurgaon, Haryana, India K. Dayanithi 7900319475328460022056 7900319475328460022056 No Division Of Radiation Oncology, Medanta Cancer Institute, Medanta The Medicity, Gurgaon, Haryana, India D. Manigandan 7900319475328460022057 7900319475328460022057 No Division Of Radiation Oncology, Medanta Cancer Institute, Medanta The Medicity, Gurgaon, Haryana, India S.R. Mishra 7900319475328460022058 7900319475328460022058 No Division Of Radiation Oncology, Medanta Cancer Institute, Medanta The Medicity, Gurgaon, Haryana, India S.S. Bisht 7900319475328460022059 7900319475328460022059 No Division Of Radiation Oncology, Medanta Cancer Institute, Medanta The Medicity, Gurgaon, Haryana, India